Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Fund moves › Lb Pharmaceuticals › TCG Crossover GP II, LLC cut its LBRX stake below 5% (2.4%) Fund moves
Why it stands out The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Date of the event that required the filing Sep 30, 2026
Reporting period Not applicable
Filed with the SEC Nov 16, 2026 passive 5% holder
Context Change vs prior quarter Undefined
Compared with the manager's prior 13F
Tracked managers with the same change NaN
For the same quarter
0001193125-26-464051
Data quality Verified: identifiers matched exactly
Around the same time Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider filing
Traded Oct 9 · filed 4 days later
Compensation award — excluded from discretionary-purchase analysis.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Aug 11, 2026 Company filing · Form 8-K · Results Reported its results Sep 3, 2026 Company filing · Form 8-K · Executive change, Reg FD Changed a top executive or board member, and shared information with investors “On September 3, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Joseph M. Miller has been appointed to serve as the Company’s Chief Financial Officer, effective as of September 2, 2026 (the “Start Date”).” Sep 15, 2026 Company filing · Form 8-K · Executive change, Reg FD Changed a top executive or board member, and shared information with investors “On September 15, 2026, LB Pharmaceuticals Inc (the “Company”) announced that Susan G. Kozauer, M.D. has been appointed to serve as the Company’s Chief Medical Officer, effective as of September 14, 2026 (the “Start Date”).” What came next Oct 13, 2026 5% stake JPMORGAN CHASE & CO. reported a passive stake (13G) of 4.3% Nov 5, 2026 Company filing · Form 8-K · Results Reported its results Nov 16, 2026 5% stake Trails Edge Capital Partners, LP reported a passive stake (13G) of 3.6% Nov 16, 2026